Psychiatric Manifestation in Patients with Parkinson's Disease

Han, Ji Won; Ahn, Yebin D.; Kim, Won‐Seok; Shin, Cheol Min; Jeong, Seong Jin; Song, Yoo Sung; Bae, Yun Jung; Kim, Jong Min

doi:10.3346/jkms.2018.33.e300

Cited by 91 publications

(69 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In moderate PD, Tandberg and colleagues 22 found that individuals with PD had a higher prevalence of DMS (39% vs. 12%, P < 0.01), but not DIS (32% vs. 22%, P > 0.05), than non-PD sleepers. In the Parkinson's and non-motor symptoms (PRIAMO) multicenter study, Barone and colleagues 23 found that in patients with moderate PD, 36.9% reported insomnia…”

Section: Insomnia Complaints In Pdmentioning

confidence: 99%

“…17,19,33,35 In adjusted models controlling for PD severity, duration, sex, medications, and other covariates, Gjerstad and colleagues 19 reported that depressive symptoms were significantly associated with insomnia symptoms. Although anxiety disorders often coexist with depression in PD, 36 studies controlling for anxiety and depressive symptoms concurrently show that depression may be the stronger predictor of insomnia symptoms in PD. 33,35 PD-related psychosis and nocturnal hallucinations can also contribute to sleep disruption.…”

Section: Nonmotor Psychiatric Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review

Wallace

Wohlgemuth

Trotti

et al. 2020

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background Insomnia is one of the most common nonmotor features of Parkinson's disease (PD). However, there are few practical guidelines for providers on how to best evaluate and treat this problem. Methods and Findings This review was developed to provide clinicians with a pragmatic approach to assessing and managing insomnia in PD. Recommendations were based on literature review and expert opinion. We addressed the following topics in this review: prevalence of insomnia in PD, sleep–wake mechanisms, theoretical models of insomnia, risk factors, assessment, pharmacologic and nonpharmacologic treatments. Insomnia treatment choices may be guided by PD severity, comorbidities, and patient preference. However, there is limited evidence supporting pharmacotherapy and nonpharmacologic treatments of insomnia in PD. Conclusions We provide a pragmatic algorithm for evaluating and treating insomnia in PD based on the literature and our clinical experience. We propose personalized insomnia treatment approaches based on age and other issues. Gaps in the existing literature and future directions in the treatment of insomnia in PD are also highlighted.

show abstract

Section: Insomnia Complaints In Pdmentioning

confidence: 99%

Section: Nonmotor Psychiatric Factorsmentioning

confidence: 99%

Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review

Wallace

Wohlgemuth

Trotti

et al. 2020

Movement Disord Clin Pract

View full text Add to dashboard Cite

show abstract

“…Anxiety is common at all stages of PD: from the premotor period to the advanced stages of the disease [11,45,46]. Even in the classic Essay on tremor palsy, J. Parkinson noted the importance of anxiety symptoms in the dynamics of PD [47].…”

Section: Anxiety and The Spectrum Of Anxiety Disordersmentioning

confidence: 99%

“…There is increase in the frequency of seeking psychiatric care during the premotor phase of PD [10]. Despite the abundance of PPD, the attention of clinicians is focused on the motor sphere, and psychopathological symptoms remain unrecognized, due to the symptomatic "overlap" of psychiatric and motor complaints [11]. There are different views on the origin of PPD.…”

mentioning

confidence: 99%

Affective and personality disorders in Parkinson's disease premotor phase. Pilot study.

Samushiya¹,

Ragimova²,

Смоленцева³

et al. 2020

Cogn. Remediat. J.

View full text Add to dashboard Cite

Neuropsychiatric symptoms are one of the factors determining quality of life among Parkinson's disease patients, but often remain underestimated by clinicians, especially in early disease stage. Objective: to study the clinical features of affective disorders and comorbid personality traits in prodrome of Parkinson's disease (PD) and their effect on treatment adherence. Materials and methods: 29 patients with PD were studied with questionnaires (Toronto alexithymia scale (TAS); Minimult personal questionnaire; DSM-IV criteria (SCID-II); Hospital anxiety and depression scale (HADS); Hamilton Scale for the Assessment of Depression (HAM-D)), and clinical-psychopathological method with objective information collection, neurological examination and neuropsychological testing. Results: Among the patients with PD, personality premorbid features cluster C were most prominent (48% patients). Affective disorders in the prodromal period of PD are dysthymia (13.7%); cyclothymia (6.8%); recurrent depressive disorder (34.4%); and single depressive episode (44.8%). Affective disorders in PD are characterized by late onset, the prevalence of anxiety, asthenic-apathetic symptoms, as well as a high level of alexithymia and somatization. We found the relationship of personality traits and adherence to therapy: the least compliant are histrionic n = 3 (10.3%) and schizotypal n = 2 (6.9%) patients. A high prevalence of dissociative reactions (55%) was noted in response to a diagnosis of PD, which is similar to cancer patients.

show abstract

“…Although PD is generally considered to be a typical dyskinesia, basically all patients with PD are complicated with nonmotor symptoms, thus increasing the overall burden of PD [4]. Advances in the studies of PD have increasingly focused on the nonmotor symptoms of PD, which mainly include depression, anxiety, sleep disorders, and cognitive dysfunction [5]; depression in PD (dPD) is the most common nonmotor symptom in patients with PD [6,7] Numerous studies have demonstrated that compared with motor symptoms, nonmotor symptoms, especially depression and cognitive dysfunction, have greater effects on the quality of life of patients with PD [8]. If early diagnosis and reasonable treatments of nonmotor symptoms in patients with PD can be realized, the quality of life of the patients can be greatly improved and the burdens of their families and society as a whole can be reduced.…”

Section: Introductionmentioning

confidence: 99%

Comparative analysis of the effects of antidepressant therapy on emotional improvement in patients with Parkinson’s disease complicated with depression

Chen¹,

Xu²,

Guo³

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective This study aimed to compare the effects of different antidepressant therapies on emotional improvement in patients with Parkinson’s disease (PD) complicated with depression, and to explore effective strategies in PD treatment. Methods A total of 328 patients with idiopathic PD admitted to the Affiliated Hospital of Guizhou Medical University and Second People’s Hospital of Guiyang were consecutively selected. The 17-item Hamilton Depression Scale (HAMD-17) was used to screen whether patients with PD exhibited depressive symptoms. The treatment group included 131 eligible patients, but 118 completed the study. The patients were randomized to conventional treatment, conventional treatment + escitalopram, conventional treatment + pramipexole, and conventional treatment + transcranial magnetic stimulation (TMS) groups. The effects of antidepressant therapies were assessed using the HAMD score reduction rate after 2 and 4 weeks of treatment. Results The prevalence of PD complicated with depression was 53.4%, and was significantly higher in females than in males. The response rate in the conventional treatment, escitalopram, pramipexole, and TMS groups was 34.48%, 93.10%, 87.09%, and 75.86%, respectively. This indicated that the escitalopram group had the best efficacy. After 2 and 4 weeks of treatment, the HAMD scores of each group were significantly lower than those before treatment. The reduction in HAMD scores was the most significant in the pramipexole group after 2 weeks of treatment and in the escitalopram group after 4 weeks of treatment. Conclusion Escitalopram, pramipexole, and high-frequency TMS had better efficacy in patients with PD complicated with depression, with escitalopram being the most effective.

show abstract

Psychiatric Manifestation in Patients with Parkinson's Disease

Cited by 91 publications

References 77 publications

Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review

Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review

Affective and personality disorders in Parkinson's disease premotor phase. Pilot study.

Comparative analysis of the effects of antidepressant therapy on emotional improvement in patients with Parkinson’s disease complicated with depression

Contact Info

Product

Resources

About